Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Conditions: Antiphospholipid Syndrome (APS); Bullous Pemphigoid (BP); Beh çet ' s Syndrome (BS); Dermatomyositis (DM); Immune-mediated Necrotizing Myopathy (IMNM); Immune Thrombocytopenia (ITP) Interventions: Drug: RAY121 Sponsors: Chugai Pharmaceutical Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
Conditions: Systemic Lupus Erythematosus; Systemic Sclerosis; Dermatomyositis; Polymyositis Interventions: Drug: anti-CD19 CAR T cell therapy Sponsors: University of Erlangen-N ürnberg Medical School Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Rheumatology Diet Study
Conditions: Diet Habit; Rheumatologic Disease; Autoimmune Diseases; Rheumatoid Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Dermatomyositis/Polymyositis; Sjogren ' s Syndrome; Systemic Lupus Erythematous; Scleroderma; Fibromyalgia Sponsors: University of Central Florida Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
Conditions: Dermatomyositis Interventions: Biological: KYV-101 Sponsors: Stanford University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials
A Study of Empasiprubart's Effect on the Body, Levels in the Blood, Effectiveness, and Safety in Adults With Dermatomyositis
Conditions: Dermatomyositis Interventions: Biological: Empasiprubart IV; Other: Placebo IV Sponsors: argenx Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
Conditions: Dermatomyositis; Myositis Interventions: Biological: Empasiprubart IV; Other: Placebo IV Sponsors: argenx Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
Conditions: Microbiome; Immune Function; Anti-MDA5 Antibody Positive Dermatomyositis Sponsors: Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy
Conditions: Idiopathic Inflammatory Myopathy; Dermatomyositis; Anti-Synthetase Syndrome; Immune-Mediated Necrotizing Myopathy Interventions: Biological: CAB-201 following preconditioning with fludarabine and cyclophosphamide Sponsors: Cabaletta Bio Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 4, 2023 Category: Research Source Type: clinical trials
Study on Lymphocyte Subsets of Peripheral Blood in Patients With Nonmyopathic Dermatomyositis Complicated With Pulmonary Interstitial Disease
Conditions: Dermatomyositis Sponsors: Yanfeng Hou Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 28, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
Conditions: SLE (Systemic Lupus); Sjogren's Syndrome; Systemic Scleroderma; Dermatomyositis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Intervention: Biological: CD19 targeted CAR-T cells Sponsor: Chongqing Precision Biotech Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
Conditions: SLE (Systemic Lupus); Sjogren ' s Syndrome; Systemic Scleroderma; Dermatomyositis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Interventions: Biological: CD19 targeted CAR-T cells Sponsors: Chongqing Precision Biotech Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis
Condition: Dermatomyositis Intervention: Other: evaluation of clinical severity Sponsor: Central Hospital, Nancy, France Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2023 Category: Research Source Type: clinical trials
